Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Phase 3VamikibartPositive

AI Analysis

Summary

Genentech presented one-year Phase III data for Vamikibart in uveitic macular edema, a serious vision loss condition. No specific efficacy or safety details were provided in the article.

Clinical Trial Data

Phase

Phase 3

Outcome Details

One-year data presentation

Importance:6/10

Sentiment:

0.50

Phase 3ophthalmologyuveitic macular edemadata presentation

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on October 10, 2026 9:40 PM

Read Original